This study evaluates how the drug dupilumab can help prevent or slow down lung function decline in adults with uncontrolled moderate to severe asthma. Asthma is a condition where your airways narrow and swell, making breathing difficult. The study compares dupilumab to standard asthma treatments. Participants will be randomly divided into two groups. The study lasts about 3 years, including 4 weeks of screening, a 3-year treatment period, and a follow-up for up to 12 weeks.

• Participants must be 18 or older with a diagnosis of asthma for at least a year.
• Patients must have had at least one severe asthma attack in the past year.
• Participants must not have other lung diseases or infections.

Before joining, you'll need to meet certain health criteria, and there will be checks and tests to ensure safety. Potential risks may include reactions to dupilumab or changes in asthma symptoms. If you have any more questions, talk to your doctor or the study team.